RGNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Regenxbio Inc (RGNX) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there are some positive aspects such as YoY financial improvements and ongoing developments in key programs, the stock faces significant legal challenges, reduced analyst price targets, and negative sentiment from recent events. The lack of strong trading signals and the absence of clear upward momentum further suggest holding off on investment for now.
The MACD histogram is positive at 0.151, indicating a bullish trend, but it is contracting. RSI is neutral at 62.447, and moving averages are converging, showing no clear trend. The stock is trading near its R1 resistance level of 9.455, with key support at 8.309.
Revenue increased by 43.00% YoY in Q4 2025, with gross margin improving to 80.46%. Analysts maintain Buy ratings despite lowered price targets, citing potential catalysts in RGX-202 and ABBV-RGX-314 programs.
Class action lawsuits related to RGX-111 gene therapy have created negative sentiment. FDA's Complete Response Letter for RGX-121 and clinical holds on RGX-111 and RGX-121 raise concerns about regulatory hurdles. Analysts have significantly lowered price targets, and the stock is underperforming with a bearish short-term outlook.
In Q4 2025, revenue grew by 43.00% YoY to $30.34M, net income improved by 31.19% YoY but remains negative at -$67.15M, and EPS increased by 28.71% YoY to -1.3. Gross margin improved to 80.46%, indicating operational efficiency.
Analysts maintain Buy ratings but have lowered price targets significantly, with the highest target now at $45 (down from $50) and the lowest at $12. Analysts highlight potential catalysts in RGX-202 and ABBV-RGX-314 but express concerns over regulatory challenges and legal issues.
